抗人 XPNPEP2 抗体对
01AB00988
X-prolyl aminopeptidase 2 (XPNPEP2) is a membrane-bound metalloprotease that catalyzes the removal of penultimate prolyl residues from N-termini of peptides, such as Arg-Pro-Pro. It belongs to the M24 family of metalloproteases and is widely expressed in human tissues, with highest levels in the kidney. XPNPEP2 is a GPI-anchored protein with 674 amino acids and plays a role in the metabolism of bioactive peptides like bradykinin. The enzyme is involved in proteolysis and has metal ion binding and metalloaminopeptidase activities. XPNPEP2 has been associated with several diseases, including angioedema, experimental liver cirrhosis, and primary ovarian insufficiency. Recent studies have also linked XPNPEP2 to cancer progression, with overexpression observed in cervical cancer and association with lymph node metastasis in prostate cancer patients.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- XPNPEP2
- 蛋白别名
- X-prolyl aminopeptidase 2; XPNPEP2
- UniProt
- O43895
- 物种
- Human
产品详情
- 靶点名称
- XPNPEP2
- 蛋白名称
- X-prolyl aminopeptidase 2
- 蛋白别名
- Xaa-Pro aminopeptidase 2; Aminoacylproline aminopeptidase; Membrane-bound aminopeptidase P; Membrane-bound APP; Membrane-bound AmP; mAmP; X-Pro aminopeptidase 2
- 靶点基因名
- XPNPEP2
- UniProt
- O43895
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
X-prolyl aminopeptidase 2 (XPNPEP2) is a membrane-bound metalloprotease that catalyzes the removal of penultimate prolyl residues from N-termini of peptides, such as Arg-Pro-Pro. It belongs to the M24 family of metalloproteases and is widely expressed in human tissues, with highest levels in the kidney. XPNPEP2 is a GPI-anchored protein with 674 amino acids and plays a role in the metabolism of bioactive peptides like bradykinin. The enzyme is involved in proteolysis and has metal ion binding and metalloaminopeptidase activities. XPNPEP2 has been associated with several diseases, including angioedema, experimental liver cirrhosis, and primary ovarian insufficiency. Recent studies have also linked XPNPEP2 to cancer progression, with overexpression observed in cervical cancer and association with lymph node metastasis in prostate cancer patients.